Humana Inc. (HUM) Down 4.6% — Time to Wave the White Flag?

  • HUM fell 4.64% to $439.83 from $461.25 the previous trading day
  • Weiss Ratings assigns C (Hold)
  • Market cap is $55.40B with a dividend yield of 0.77%

Humana Inc. (HUM) is struggling in Tuesday's session, last changing hands at $439.83 on the NYSE, down $21.42 from the prior close of $461.25. The reversal comes immediately after a strong run. Just one session earlier, on November 16, 2026, the stock set a 52-week high of $462.87, and today's decline leaves it about 5.0% below that level. The size of the turn shows how quickly sentiment toward managed care can shift when the policy backdrop changes.

Volume so far stands at roughly 871,000 shares, against a 90-day average of about 1.38 million. With the regular session still open, turnover is tracking at about 63% of a typical full day.


Why Humana Inc. Price is Moving Lower

The most plausible driver is new regulatory risk for Medicare Advantage insurers, and the selling is spread across the group. On November 16, the Centers for Medicare & Medicaid Services proposed its CRUSH rule. The proposal would expand Medicare Advantage audits, apply audit findings back to payment year 2018, and make it easier for the government to recover overpayments. CMS estimates the audit changes could recover about $9 billion per payment year.

The rule is only a proposal and is not final. Still, the prospect of payments from as far back as 2018 being challenged is a direct concern for Humana, whose business is built on government-sponsored Medicare plans. The timing is awkward for the stock, because the proposal landed on the same day HUM reached its 52-week high.

Managed care stocks are moving together, which supports the view that this is a sector repricing rather than a Humana-specific problem. UnitedHealth Group Incorporated (UNH) is down 5.83% today, a steeper decline than Humana's. Elevance Health, Inc. (ELV) is off 2.88%. The S&P 500 was also down 1.31%, so a weak broader tape is adding to the pressure. Political rhetoric has piled on as well. Senator Elizabeth Warren called for breaking up large healthcare companies, although she named CVS, UnitedHealth, and Cigna rather than Humana.

Recent fundamentals do not explain the drop. Humana's Q3 report on November 6 came in ahead of expectations. The adjusted loss was $0.70 per share, better than the $1.00 loss analysts expected. Revenue reached $41.16 billion against a $40.87 billion consensus, up 26.1% year over year. The insurance benefit ratio of 93.7% also beat management's forecast of "slightly above 94%." On that strength, Humana raised its 2026 adjusted EPS floor to $9.50 from $9.00.

The report was not clean on every line, however. GAAP EPS fell to $1.33 from $1.62 a year earlier, a reminder that profitability remains thin even as revenue expands. That leaves little room to absorb a new layer of regulatory clawback risk.


What is the Humana Inc. Rating - Should I Sell?

Weiss Ratings assigns HUM a C rating. Current recommendation is Hold. The rating reflects a company with a sturdy financial foundation that is still struggling to convert rapid top-line expansion into meaningful earnings. Today's policy-driven selloff shows how exposed that earnings base is to decisions made in Washington.

The balance sheet is where Humana looks strongest. Its Excellent rating on the Solvency Index suggests the company can withstand a period of regulatory uncertainty, including the possibility of audit-related repayments, without immediate financial strain. The Good rating on the Efficiency Index reflects a 6.74% ROE. That figure is modest in absolute terms, but it holds up for an insurer working through elevated medical cost trends, and the third-quarter benefit ratio of 93.7%, better than management's own forecast, points to improving cost discipline. The Total Return Index is also rated Good, consistent with a stock that climbed all the way to a fresh 52-week high of $462.87 before today's pullback.

Where the picture becomes more nuanced is growth and stability. The Weak rating on the Growth Index may look odd next to 26.05% revenue growth. The explanation is that the expansion is not reaching the bottom line. Profit margin sits at just 0.80%, and GAAP EPS declined year over year to $1.33 from $1.62. The forward P/E of 44.89 adds valuation risk, since a multiple that high leaves the shares vulnerable when policy headlines threaten future earnings.

The Weak Volatility Index is illustrated by today's move. A 4.64% single-session drop, driven by a proposed CMS audit rule, erased the prior day's gain to a 52-week high. The Dividend Index is also rated Weak. A 0.77% yield offers little income cushion while investors wait for the regulatory picture to clarify.

Within the Health Care sector, Humana sits alongside UnitedHealth Group Incorporated (UNH, C), Elevance Health, Inc. (ELV, C), and Abbott Laboratories (ABT, C). The uniformity across the managed care names is notable. The Weiss framework sees similar risk/reward tradeoffs across the group, and today's coordinated decline shows that shared regulatory exposure is a defining part of that risk.


About Humana Inc.

Humana Inc. (HUM) is a Health Care company founded in 1961 and headquartered in Louisville, Kentucky, and one of the largest health benefits providers focused on government-sponsored programs. Medicare Advantage is the core of the business. Humana is one of the largest Medicare Advantage carriers in the country, offering plans that bundle hospital, physician, and often prescription drug coverage for seniors. It also provides stand-alone Medicare Part D prescription drug plans, state Medicaid managed care contracts, and military health coverage through the TRICARE East Region contract.

Alongside its insurance operations, Humana runs CenterWell, a health care services platform that gives it a direct role in delivering care. CenterWell Senior Primary Care operates clinics built around value-based models for older adults. CenterWell Pharmacy provides mail-order and specialty pharmacy services, and CenterWell Home Health delivers in-home clinical care. This mix lets Humana manage more of the patient relationship and capture economics beyond premium income.

Humana's main competitive advantages are its deep specialization in the senior market, its scale in Medicare Advantage enrollment, and its integrated care-delivery assets, which few rivals can match in the same concentrated way. That same focus is also its central vulnerability. Because so much of the business depends on federal reimbursement, changes to Medicare Advantage rates, star ratings, and audit policy can affect Humana more directly than more diversified insurers.


Investor Outlook

Humana Inc. (HUM) carries a Weiss Rating of C (Hold). With a proposed CMS audit rule now hanging over Medicare Advantage payments dating back to 2018, caution is warranted even after an earnings beat and a raised EPS floor of $9.50. Investors should watch whether the CRUSH proposal is softened or finalized as written, how Humana quantifies any potential exposure, and whether the improved benefit ratio holds into year-end. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.

--

This Weiss Instant News Alert was compiled by narrative data technology, our proprietary ratings models and analysis by Weiss Ratings with the intent of providing our readers with the fastest research and independent coverage. Weiss Instant News Alerts have been reviewed by a member of our editorial staff before publication. Please send any questions or comments about this story to [email protected]
Top Tech Stocks
See All »
B
AAPL NASDAQ $355.04
B
MSFT NASDAQ $505.55
B
NVDA NASDAQ $154.28
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $126.70
B
Top Financial Stocks
See All »
B
A
JPM NYSE $328.78
B
V NYSE $413.53
Top Energy Stocks
See All »
B
CVX NYSE $209.12
B
COP NYSE $137.22
Top Health Care Stocks
See All »
B
LLY NYSE $1,403.40
B
JNJ NYSE $276.72
B
ABBV NYSE $290.00
Top Real Estate Stocks
See All »
B
PLD NYSE $125.20